Section

Biology

Genomes, cells, brains, and the tools that read and write them.

Daily at 05:45 UTC

Edition No. 32
Updated UTC

Stronger verdicts first · Score orders stories within each verdict

Europe PMC

Verdict: Major

Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China

Izalontamab brengitecan (iza-bren) is a first-in-class bispecific antibody-drug conjugate targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3) and has shown…

By Hong, Zhou, Hou +43Lancet (London, England)

Score█████░░░░░4.8

Top stories

  1. 1. Rare and common genetic variants shape single-cell immune gene expression

    Understanding the genetic basis of gene expression can shed light on the regulatory mechanisms underlying complex traits and diseases1,2.

    Verdict: Notable█████░░░░░4.8
  2. 2. Phenologs at knowledge-graph scale: a mouse-to-slime-mold catalog of candidate genes for thousands of human diseases

    Model organisms carry decades of systematic gene-phenotype annotation, but connecting those annotations to human disease is rarely straightforward.

    Verdict: Notable█████░░░░░4.7
  3. 3. Genetic variants shape single-cell chromatin accessibility and disease risk

    Understanding how genetic variation shapes gene regulation at single-cell resolution is crucial for elucidating complex disease mechanisms1, but has been limited by the lack of large-scale single-cell multi-omics…

    Verdict: Notable█████░░░░░4.6

More top stories

No.04 to No.06

  1. Europe PMCby Xu, Zhang, Lin +35

    Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China

    Ruzaltatug rezetecan is a novel HER3-directed antibody-drug conjugate that has shown promising antitumour activity and manageable safety in pretreated EGFR-.mutated non-small-cell lung ....

    No.05Verdict: MajorScore████░░░░░░4.5

Briefs

8 more from the desk